Physician

Yaman Suleiman, MD

According to 2025 Medicare claims, Yaman Suleiman, MD (NPI: 1003128703) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Orange, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32789-2988.

Suleiman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 802 traditional Medicare patients, billed 228,620 HCPCS/CPT codes, and received $4,201,488 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,152 prescription claims across 348 beneficiaries totaling $5,234,060 in drug costs, led by Revlimid (Lenalidomide). DME data shows 35 claims. Open Payments data shows 46 records totaling $1,119. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $2,255 to $5,234,060. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,717 to $211.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	256	20,878	$390,713
2017	700	106,569	$1,636,125
2018	984	298,708	$3,368,857
2019	907	430,385	$5,148,768
2020	961	474,776	$5,759,599
2021	872	361,760	$4,729,328
2022	765	305,038	$4,426,982
2023	692	241,357	$3,644,910
2024	802	228,620	$4,201,488

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	21	27	$2,255
2016	68	131	$150,659
2017	186	659	$925,274
2018	227	1,224	$2,250,121
2019	229	1,284	$2,055,004
2020	263	1,454	$1,885,191
2021	302	1,798	$3,126,414
2022	305	2,262	$5,337,521
2023	344	2,151	$5,501,604
2024	348	2,152	$5,234,060

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	54	$8,312
2019	N/R	101	$82,810
2020	N/R	58	$51,862
2021	N/R	35	$50,658
2022	N/R	102	$58,913
2023	N/R	41	$8,216
2024	N/R	35	$50,599

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	503	1,362	$94
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	470	993	$13
96372	Injection of drug or substance under skin or into muscle	207	1,131	$10
36415	Insertion of needle into vein for collection of blood sample	667	2,379	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	673	2,382	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	52	1,449	$815,652
Tagrisso	Osimertinib Mesylate	32	936	$615,491
Xtandi	Enzalutamide	36	1,080	$493,590
Idhifa	Enasidenib Mesylate	12	360	$399,064
Lenvima	Lenvatinib Mesylate	16	480	$394,023

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	17	$44,854
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	18	$5,746

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	46	$1,119	Bayer Healthcare Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Yaman Suleiman, MD?

Tedicare shows public-source Medicare data for Yaman Suleiman, MD (NPI 1003128703), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Yaman Suleiman, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Yaman Suleiman, MD?

Yaman Suleiman, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Yaman Suleiman, MD have Open Payments data?

Yaman Suleiman, MD has 46 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.